RecruitingNCT07076147
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
Sponsor
University of Southern California
Enrollment
150 participants
Start Date
Jun 2, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study assesses breast cancer screening adherence for women at moderately increased risk for developing breast cancer based on gene mutation status or empiric risk model estimates. It also seeks to determine facilitators and barriers to screening.
Eligibility
Sex: FEMALEMin Age: 30 YearsMax Age: 75 Years
Inclusion Criteria8
- \* \>= 30 years
- =\< 75 years
- Women with either:
- Genetic test results showing moderately increased breast cancer risk due to a pathogenic/likely pathogenic variant in ATM, CHEK2, BARD1, RAD51C, or RAD51D (Mutation carrier group) OR
- Calculated lifetime breast cancer risk estimates between 20% and 40% according to the Tyrer-Cuzick V8.0B empiric risk model (Empiric risk group)
- Patients provided breast cancer risk assessments by genetic counselors at USC Norris or LA General Hospital beginning in 2021 and at least 12 months ago
- Women recommended to undergo annual breast MRI and/or annual mammogram beginning at the time of their genetic counseling risk assessment
- English or Spanish speaking patients
Exclusion Criteria4
- \* History of breast cancer before genetic counseling at University of Southern California (USC)
- Any metastatic cancer diagnosis at time of genetic counseling risk assessment
- Deceased
- Patient underwent a risk reducing mastectomy before their genetic counseling risk assessment
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07076147
Related Trials
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204467 locations
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT0618475011 locations
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT059415204 locations
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589836 locations
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT061953063 locations